FLEETCOR-TECHNOLOGIES
FLEETCOR Technologies, Inc. (NYSE: FLT), a leading global business payments company, announced today the acquisition of Plugsurfing, a leading European electric vehicle (EV) software and network provider to vehicle OEMs, charge point operators (CPO), and fleets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220831005602/en/
“The acquisition demonstrates FLEETCOR®’s commitment to developing world-class EV solutions for our thousands of commercial fleet customers, including access to European EV roaming capabilities and software applications for drivers and fleet managers,” said Tom Rowlands, global managing director of EV at FLEETCOR. “In addition, Plugsurfing allows us to pursue new customer segments by serving CPOs with software to manage their charging infrastructure and providing OEMs with a white-label EV solution. We’re excited to have Plugsurfing join the FLEETCOR family.”
Plugsurfing has developed a proprietary EV charging network in Europe with over 300,000 charge points, or nearly 80% of all charge points in Europe. The Plugsurfing app provides access to comprehensive tariff information and facilitates payment for EV charging. This capability is an essential tool for EV drivers and is available directly and as a turnkey white-label solution to EV OEMs for distribution to their customers.
In addition, Plugsurfing also serves CPOs with API, cloud-based operating software that enables CPOs to run their hardware efficiently and effectively, including managing payments of charging events.
Since its founding in 2012, Plugsurfing has processed about 20 million charging sessions and has been at the forefront of consolidating and simplifying the European EV ecosystem.
“We’re thrilled to bring a boost to the electric future in Europe through our acquisition by FLEETCOR. With their distribution and resources, we can scale our Plugsurfing platform to better serve existing and future customers on the EV journey that will continue to evolve over time. We’re excited about the prospects for continuing to help usher in an EV future,” Tatu Kulla, chief executive officer at Plugsurfing.
About FLEETCOR®
FLEETCOR Technologies (NYSE: FLT) is a leading global corporate payments company that helps businesses spend less by providing innovative solutions that enable and control expense-related purchasing and payment processes. The FLEETCOR portfolio of brands automate, secure, digitize and manage payment transactions on behalf of businesses across more than 100 countries in North America, Latin America, Europe, and Asia Pacific. For more information, please visit www.FLEETCOR.com.
About Plugsurfing
Plugsurfing aligns the entire car charging ecosystem—drivers, charging point operators, and carmakers—within a single platform. The over one million drivers connected to our platform benefit from a network of over 300,000 charging points across Europe and a reliable experience through our app or solutions designed for our partners. We serve charging point operators with a back-end cloud software for managing everything from country-specific regulations to providing diverse payment options for customers. Carmakers benefit from white label solutions as well as deeper integrations with their in-house technology. For more information, please visit www.plugsurfing.com.
###
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220831005602/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TII Launches Falcon Reasoning: Best 7B AI Model Globally, Also Outperforms Larger Models5.1.2026 14:54:00 CET | Press release
Falcon H1R 7B Packs Advanced Reasoning into a Compact 7 Billion Parameter Model Optimized for Speed and Efficiency TII’s Latest AI Model Outperforms Larger Rivals from Microsoft, Alibaba, and NVIDIA on Key Benchmarks The Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), has announced the release of Falcon H1R 7B, a next-generation AI model that takes a significant step toward making advanced AI more accessible than ever, by delivering world-class reasoning performance in a compact, efficient, and openly available format. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105981339/en/ TII Launches Falcon Reasoning: Best 7B AI Model Globally, Also Outperforms Larger Models (Graphic: AETOSWire) With just 7 billion parameters, Falcon H1R 7B challenges and, in many cases, outperforms larger open-source AI models from around the world, including models fr
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 14:00:00 CET | Press release
Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT TechnologyWorld's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell TherapiesDrastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evalu
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release
Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom